Ensign Peak Advisors’s Anika Therapeutics ANIK Stock Holding History

Ensign Peak Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-16,300	Closed	-$304K	–	1741
2023 Q3	$304K	Hold	16,300	–	–	﹤0.01%	1690
2023 Q2	$423K	Buy	16,300 +1,400	+9%	+$37.5K	﹤0.01%	1665
2023 Q1	$428K	Buy	14,900 +4,200	+39%	+$125K	﹤0.01%	1670
2022 Q4	$317K	Buy	10,700 +4,600	+75%	+$131K	﹤0.01%	1702
2022 Q3	$145K	Hold	6,100	–	–	﹤0.01%	1988
2022 Q2	$136K	Hold	6,100	–	–	﹤0.01%	1901
2022 Q1	$153K	Hold	6,100	–	–	﹤0.01%	1946
2021 Q4	$219K	Sell	6,100 -9,700	-61%	-$388K	﹤0.01%	1907
2021 Q3	$672K	Hold	15,800	–	–	﹤0.01%	1558
2021 Q2	$684K	Hold	15,800	–	–	﹤0.01%	1539
2021 Q1	$644K	Hold	15,800	–	–	﹤0.01%	1554
2020 Q4	$715K	Sell	15,800 -200	-1%	-$7.59K	﹤0.01%	1515
2020 Q3	$566K	Hold	16,000	–	–	﹤0.01%	1500
2020 Q2	$604K	Hold	16,000	–	–	﹤0.01%	1421
2020 Q1	$463K	Hold	16,000	–	–	﹤0.01%	1410
2019 Q4	$830K	Buy	+16,000	New	+$929K	﹤0.01%	1396

Other funds holding ANIK

Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Ensign Peak Advisors's ANIK Position: Q4 2023 in Review

Ensign Peak Advisors sold out of Anika Therapeutics (ANIK) in Q4 2023, closing a stake of 16,300 shares — an estimated $304K sold.

Ensign Peak Advisors first reported a position in ANIK in Q4 2019 and held it in 16 quarters. The position peaked at $830K in Q4 2019. 117 funds tracked by Wall St. Rank hold ANIK as of Q4 2023.

Ensign Peak Advisors reported no remaining Anika Therapeutics position as of Q4 2023 after selling out during the quarter.
Ensign Peak Advisors sold 16,300 Anika Therapeutics shares in Q4 2023, an estimated $304K.
Ensign Peak Advisors first reported a position in Anika Therapeutics in Q4 2019 and held it in 16 quarters.
Ensign Peak Advisors's Anika Therapeutics position peaked at $830K in Q4 2019.
117 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2023.

Based on Ensign Peak Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.